Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined
|
Homo sapiens
|
0.26
ug.mL-1
|
|
Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression
|
Homo sapiens
|
0.7
ug.mL-1
|
|
In vitro inhibitory activity against Mouse melanoma (B16) cell line.
|
Mus musculus
|
2.6
ug.mL-1
|
|
Tested for cytotoxicity against C170 colorectal carcinoma cell line by [75Se]selenomethionine uptake assay, in vitro
|
Homo sapiens
|
0.3
ug.mL-1
|
|
Concentration at 50 percent inhibition of cell growth against human leukemia CCRF CEM cell line in vitro
|
Homo sapiens
|
0.95
ug.mL-1
|
|
The compound was evaluated for antitumoral activity against human leukemia cell line CCRF CEM after 72 hr of incubation
|
Homo sapiens
|
4.0
ug.mL-1
|
|
Concentration required for 50% inhibition of cell growth of CCRF CEM leukemic cell lines in human.
|
Homo sapiens
|
40.0
ug.mL-1
|
|
In vitro inhibitory activity against Human T-cell acute lymphoblastoid leukemia (CCRF CEM) cell line.
|
Homo sapiens
|
40.0
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human acute lymphocytic leukemia (CCRF-CEM) cells
|
Homo sapiens
|
2.1
ug.mL-1
|
|
In vitro inhibitory effect on growth of human T-cell acute lymphoblastoid leukemic CCRFCEM cell lines.
|
Homo sapiens
|
40.0
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human colon adenocarcinoma (COLO 205) cells.
|
Homo sapiens
|
0.1
ug.mL-1
|
|
Evaluated for the inhibition of tumor cell growth of Human T-Lymphocyte cells (CEM/0)
|
Homo sapiens
|
1.2
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human epidermoid carcinoma (Calu-1) cells
|
Homo sapiens
|
3.3
ug.mL-1
|
|
Evaluated for the inhibition of tumor cell growth of murine mammary carcinoma malignant tumor cell line (FM3A/0)
|
Mus musculus
|
0.02
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human osteogenic sarcoma (G-292) cells
|
Homo sapiens
|
3.3
ug.mL-1
|
|
Inhibitory concentration of compound for cytotoxicity against HCT15 human colon cells was determined
|
Homo sapiens
|
0.11
ug.mL-1
|
|
In vitro inhibitory activity against Human promyelocytic leukemia (HL-60) cell line.
|
Homo sapiens
|
1.3
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human promyelocytic leukemia (HL-60) cells
|
Homo sapiens
|
1.33
ug.mL-1
|
|
Antitumor activity against colon carcinoma cell line (HT-29)
|
Homo sapiens
|
150.0
nM
|
|
In vitro inhibitory activity against growth of Human osteogenic sarcoma (HOS) cells
|
Homo sapiens
|
0.79
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human bladder carcinoma (HT1376) cells
|
Homo sapiens
|
0.58
ug.mL-1
|
|
In vitro inhibitory concentration for cytotoxic activity was tested against HeLa cells
|
Homo sapiens
|
3.0
ug.mL-1
|
|
Percent inhibition of growth of human cervical carcinoma (HeLa) cells in culture at 0.1 micro g/mL of the compound
|
Homo sapiens
|
19.0
%
|
|
Percent inhibition of growth of human cervical carcinoma (HeLa) cells in culture at 10 micro g/mL of the compound
|
Homo sapiens
|
63.5
%
|
|
Percent inhibition of growth of human cervical carcinoma (HeLa) cells in culture at 10 micro g/mL of the compound
|
Homo sapiens
|
70.0
%
|
|
Percent inhibition of growth of human cervical carcinoma (HeLa) cells in culture at 1 micro g/mL of the compound
|
Homo sapiens
|
55.0
%
|
|
Percent inhibition of growth of human cervical carcinoma (HeLa) cells in culture at 25 micro g/mL of the compound
|
Homo sapiens
|
77.0
%
|
|
Percent inhibition of growth of human cervical carcinoma (HeLa) cells in culture at 50 micro g/mL of the compound
|
Homo sapiens
|
90.0
%
|
|
Percent inhibition of growth of human cervical carcinoma (HeLa) cells in culture at 5 micro g/mL of the compound
|
Homo sapiens
|
34.3
%
|
|
Compound was tested in vitro for cytotoxicity against HeLa cells.
|
Homo sapiens
|
6.0
ug
|
|
In vitro antitumor activity in IM-9 cell lines
|
Homo sapiens
|
0.34
ug.mL-1
|
|
Growth inhibition in L1210 mouse Leukemia cells for a treatment time of 24 hr
|
Mus musculus
|
220.0
nM
|
|
Growth inhibition in L1210 mouse Leukemia cells for a treatment time of 48 hr
|
Mus musculus
|
125.0
nM
|
|
Growth inhibition in L1210 mouse Leukemia cells for a treatment time of 8 hr
|
Mus musculus
|
630.0
nM
|
|
In vitro inhibitory activity against growth of Human chronic myelogenous leukemia (K562 cells
|
Homo sapiens
|
2.2
ug.mL-1
|
|
In vitro inhibitory effect on growth of human chronic myelogenous leukemic K562 cell lines.
|
Homo sapiens
|
38.0
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human renal-cell carcinoma (KU-2) cells
|
Homo sapiens
|
0.28
ug.mL-1
|
|
Concentration required for 50% inhibition of cell growth of K562 leukemic cell lines in human.
|
Homo sapiens
|
3.8
ug.mL-1
|
|
In vitro inhibitory activity against Human gastric carcinoma (KATO III) cell line.
|
Homo sapiens
|
3.7
ug.mL-1
|
|
Concentration required for 50% inhibition of human lung squamous cell carcinoma KATO III solid cell lines.
|
Homo sapiens
|
3.7
ug.mL-1
|
|
Concentration at 50 percent inhibition of cell growth against human cancer KB cell line in vitro
|
Homo sapiens
|
12.1
ug.mL-1
|
|
In vitro inhibitory activity against Human oral epidermoid carcinoma (KB) cell line.
|
Homo sapiens
|
12.1
ug.mL-1
|
|
In vitro antitumor activity in K-562 cell lines
|
Homo sapiens
|
4.3
ug.mL-1
|
|
Growth inhibition in L1210 mouse leukemia cells after 24 h treatment
|
Mus musculus
|
360.0
nM
|
|
Growth inhibition in L1210 mouse leukemia cells after 48 hr treatment
|
Mus musculus
|
200.0
nM
|
|
In vitro inhibitory effect on growth of mouse leukemic L1210 cell lines.
|
Mus musculus
|
0.32
ug.mL-1
|
|
Evaluated in vitro for the Cytotoxic activity in the L1210 cell culture screen at 1 uM Maximum cell kill in a 72-h period
|
Mus musculus
|
79.8
%
|
|
Evaluated in vitro for the Cytotoxic activity in the L1210 cell culture screen at 10 uM Maximum cell kill in a 72-h period
|
Mus musculus
|
81.2
%
|
|
Evaluated in vitro for the Cytotoxic activity in the L1210 cell culture screen at 100 uM Maximum cell kill in a 72-h period
|
Mus musculus
|
90.3
%
|
|
Inhibition of cell growth of L1210 mouse Leukemia cells
|
Mus musculus
|
300.0
nM
|
|
Concentration at 50 percent inhibition of cell growth against mouse leukemia 1210 cell line in vitro
|
Mus musculus
|
0.36
ug.mL-1
|
|
Concentration required for the 50% inhibition of growth of L1210 mouse leukemia cells in culture
|
Mus musculus
|
500.0
nM
|
|
In vitro cytotoxicity against murine Leukemia L1210 cells.
|
Mus musculus
|
620.0
nM
|
|
In vitro growth inhibition of L1210 cells 24 hours after administration of compound
|
Mus musculus
|
220.0
nM
|
|
In vitro growth inhibition of L1210 cells 48 hours after administration of compound
|
Mus musculus
|
120.0
nM
|
|
In vitro growth inhibition of L1210 cells 8 hours after administration of compound
|
Mus musculus
|
630.0
nM
|
|
Evaluated for the inhibition of tumor cell growth of murine leukemia malignant tumor cell line (L1210/0)
|
Mus musculus
|
0.04
ug.mL-1
|
|
Effect on L1210/0 cells in culture
|
Mus musculus
|
300.0
nM
|
|
The compound was evaluated for antitumoral activity against mouse leukemia cell line L1210/c after 72 hr of incubation
|
Mus musculus
|
0.2
ug.mL-1
|
|
Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse.
|
Mus musculus
|
0.32
ug.mL-1
|
|
In vitro inhibitory effect on growth of human T-cell acute lymphoblastic leukemic MOLT 4 cell lines.
|
Homo sapiens
|
3.8
ug.mL-1
|
|
In vitro antitumor activity in MOLT-3 cell lines
|
Homo sapiens
|
1.2
ug.mL-1
|
|
In vitro inhibitory activity against Human T-cell acute lymphoblastic leukemia (MOLT-4) cell line.
|
Homo sapiens
|
3.8
ug.mL-1
|
|
Concentration required for 50% inhibition of cell growth of MOLT-4 leukemic cell lines in human.
|
Homo sapiens
|
3.8
ug.mL-1
|
|
Evaluated for the inhibition of tumor cell growth of Human T-Lymphocyte cells (Molt4/C8)
|
Homo sapiens
|
2.9
ug.mL-1
|
|
Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 10 mg/kg orally on day 20
|
Mus musculus
|
1.0
%
|
|
Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 20 mg/kg orally on day 20
|
Mus musculus
|
6.0
%
|
|
Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 30 mg/kg orally on day 20
|
Mus musculus
|
9.0
%
|
|
Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 40 mg/kg orally on day 20
|
Mus musculus
|
17.0
%
|
|
Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 50 mg/kg orally on day 20
|
Mus musculus
|
28.0
%
|
|
Percentage inhibition as antitumor activity in carcinoma CF1 male mice.
|
Mus musculus
|
0.0
%
|
|
The compound was evaluated for antitumoral activity against human melanoma cell line P36 after 72 hr of incubation
|
Homo sapiens
|
11.0
ug.mL-1
|
|
In vitro inhibitory activity against Human melanoma (P-36) cell line.
|
Homo sapiens
|
10.7
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human pancreas epitheloid carcinoma (PANC-1) cells
|
Homo sapiens
|
0.22
ug.mL-1
|
|
IIn vitro antitumor activity in PHA-Ly cell lines
|
Homo sapiens
|
1.4
ug.mL-1
|
|
In vitro inhibitory activity against Human lung squamous cell carcinoma (PC-10) cell line.
|
Homo sapiens
|
100.0
ug.mL-1
|
|
In vitro inhibitory activity against Human lung adenocarcinoma (PC-14) cell line.
|
Homo sapiens
|
10.0
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human lung adenocarcinoma (PC-8) cells
|
Homo sapiens
|
0.42
ug.mL-1
|
|
Concentration at 50 percent inhibition of cell growth against human cancer PC10 cell line in vitro
|
Homo sapiens
|
42.0
ug.mL-1
|
|
In vitro inhibitory effect on growth of human lung squamous cell carcinoma cell lines (PC10).
|
Homo sapiens
|
100.0
ug.mL-1
|
|
Concentration required for 50% inhibition of human lung squamous cell carcinoma PC10 solid cell lines.
|
Homo sapiens
|
100.0
ug.mL-1
|
|
Concentration required for 50% inhibition of human lung squamous cell carcinoma PC14 solid cell lines.
|
Homo sapiens
|
10.0
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human lung squamous-cell carcinoma (QG-56) cells
|
Homo sapiens
|
0.18
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human lung small cell carcinoma (QG-90) cells
|
Homo sapiens
|
0.22
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human myeloma (RPMI 8226) cells
|
Homo sapiens
|
0.07
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human osteogenic sarcoma (Saos-2) cells
|
Homo sapiens
|
0.78
ug.mL-1
|
|
Concentration required for 50% inhibition of human lung squamous cell carcinoma SW 480 solid cell lines.
|
Homo sapiens
|
3.3
ug.mL-1
|
|
In vitro inhibitory activity against Human colon adenocarcinoma (SW-480) cell line.
|
Homo sapiens
|
3.3
ug.mL-1
|
|
The compound was evaluated for antitumoral activity against human cancer cell line SW480 after 72 hr of incubation
|
Homo sapiens
|
6.0
ug.mL-1
|
|
In vitro inhibitory effect on growth of human colon adenocarcinoma cell lines (SW480).
|
Homo sapiens
|
3.3
ug.mL-1
|
|
Antitumor activity against lung carcinoma cell line (SK-MES-1)
|
Homo sapiens
|
310.0
nM
|
|
Inhibitory concentration of compound for cytotoxicity against SK-MEL-2 human melanoma cells was determined
|
Homo sapiens
|
0.63
ug.mL-1
|
|
Inhibitory concentration of compound for cytotoxicity against SK-OV-3 human ovarian cells was determined
|
Homo sapiens
|
0.03
ug.mL-1
|
|
The compound was evaluated for antitumoral activity against human cancer cell line T24 after 72 hr of incubation
|
Homo sapiens
|
6.0
ug.mL-1
|
|
In vitro inhibitory effect on growth of human bladder transitional-carcinoma cell lines (T24).
|
Homo sapiens
|
6.1
ug.mL-1
|
|
Concentration required for 50% inhibition of human lung squamous cell carcinoma T24 solid cell lines.
|
Homo sapiens
|
6.1
ug.mL-1
|
|
In vitro inhibitory activity against Human esophagus adenocarcinoma (TE-2) cell line.
|
Homo sapiens
|
3.9
ug.mL-1
|
|
In vitro inhibitory effect on growth of human esophagus adenocarcinoma cell lines (TE2).
|
Homo sapiens
|
3.9
ug.mL-1
|
|
Concentration required for 50% inhibition of human lung squamous cell carcinoma TE2 solid cell lines.
|
Homo sapiens
|
3.9
ug.mL-1
|
|
In vitro inhibitory activity against Human bladder transitional-cell carcinoma (T-24) cell line.
|
Homo sapiens
|
6.1
ug.mL-1
|
|
Tested for cytotoxicity against antigen negative T-24 bladder carcinoma cells having only 3-5% antigen expression
|
Homo sapiens
|
0.5
ug.mL-1
|
|
In vitro antitumor activity in U-937 cell lines
|
Homo sapiens
|
0.5
ug.mL-1
|
|
In vitro inhibitory activity against Human histiocytic lymphoma (U-937) cell line.
|
Homo sapiens
|
3.5
ug.mL-1
|
|
In vitro inhibitory activity against growth of Human histocytic lymphoma (U937) cells
|
Homo sapiens
|
0.11
ug.mL-1
|
|
Concentration required for 50% inhibition of cell growth of U937 leukemic cell lines in human.
|
Homo sapiens
|
3.5
ug.mL-1
|
|
Concentration required to inhibit 50% of cell growth on murine L1210 cells.
|
Mus musculus
|
280.0
nM
|
|
Concentration required to inhibit 50% of cell growth on murine P388 D1 cells.
|
Mus musculus
|
490.0
nM
|
|
Cytotoxicity against mouse L1210/0 cells after 48 hrs
|
Mus musculus
|
310.0
nM
|
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
Homo sapiens
|
160.0
nM
|
|
Antitumor activity in mouse implanted with S180 cells at 50 mg/kg, ip after 2 days
|
Mus musculus
|
80.4
%
|
|
Cytotoxicity against Vero cells
|
Chlorocebus sabaeus
|
200.0
nM
|
|
Growth inhibition of DLA cells at 62.5 ug/mL after 3 hrs
|
Mus musculus
|
100.0
%
|
|
Growth inhibition of DLA cells at 31.25 ug/mL after 3 hrs
|
Mus musculus
|
100.0
%
|
|
Growth inhibition of EAC cells at 500 ug/mL after 3 hrs
|
Mus musculus
|
100.0
%
|
|
Growth inhibition of EAC cells at 250 ug/mL after 3 hrs
|
Mus musculus
|
100.0
%
|
|
Growth inhibition of DLA cells at 15.63 ug/mL after 3 hrs
|
Mus musculus
|
73.68
%
|
|
Growth inhibition of DLA cells at 7.81 ug/mL after 3 hrs
|
Mus musculus
|
65.79
%
|
|
Growth inhibition of DLA cells at 3.91 ug/mL after 3 hrs
|
Mus musculus
|
42.11
%
|
|
Growth inhibition of EAC cells at 15.63 ug/mL after 3 hrs
|
Mus musculus
|
60.71
%
|
|
Growth inhibition of EAC cells at 7.81 ug/mL after 3 hrs
|
Mus musculus
|
32.14
%
|
|
Growth inhibition of EAC cells at 3.91 ug/mL after 3 hrs
|
Mus musculus
|
17.86
%
|
|
Cytotoxicity against human Hep 3B cells by MTT microassay
|
Homo sapiens
|
600.0
nM
|
|
Cytotoxicity against human HT29 cells by MTT microassay
|
Homo sapiens
|
600.0
nM
|
|
Antiproliferative activity against human MCF7 cells after 72 hrs
|
Homo sapiens
|
300.0
nM
|
|
Cytotoxicity against human MCF7 cells at 50 uM after 48 hrs
|
Homo sapiens
|
20.0
%
|
|
Cytotoxicity against human DU145 cells at 50 uM after 48 hrs
|
Homo sapiens
|
31.0
%
|
|
Cytotoxicity against human SW620 cells at 50 uM after 48 hrs
|
Homo sapiens
|
41.0
%
|
|
Cytotoxicity against human 502713 cells at 50 uM after 48 hrs
|
Homo sapiens
|
25.0
%
|
|
Cytotoxicity against human HT29 cells at 50 uM after 48 hrs
|
Homo sapiens
|
36.0
%
|
|
Antitumor activity in B16 cells xenografted ICR mouse assessed as tumor growth inhibition at 25 mg/kg, iv after 11 days
|
Mus musculus
|
72.4
%
|
|
Cytostatic activity against mouse L1210 cells
|
Mus musculus
|
280.0
nM
|
|
Cytotoxicity against human A549 cells by MTT assay
|
Homo sapiens
|
0.18
ug.mL-1
|
|
Cytotoxicity against human Bel 7402 cells by MTT assay
|
Homo sapiens
|
0.54
ug.mL-1
|
|
Cytotoxicity against human BGC 823 cells by MTT assay
|
Homo sapiens
|
0.7
ug.mL-1
|
|
Cytotoxicity against human HCT8 cells by MTT assay
|
Homo sapiens
|
0.54
ug.mL-1
|
|
Cytotoxicity against human A2780 cells by MTT assay
|
Homo sapiens
|
0.65
ug.mL-1
|
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
Homo sapiens
|
230.0
nM
|
|
Antiproliferative activity against mouse 26-L5 cells after 72 hrs by MTT assay
|
Mus musculus
|
310.0
nM
|
|
Cytotoxicity against human Hep3B cells by MTT assay
|
Homo sapiens
|
600.0
nM
|
|
Cytotoxicity against human HT29 cells by MTT assay
|
Homo sapiens
|
600.0
nM
|
|
Antitumor activity in mouse sarcoma 180 cells transplanted in Kunming mouse assessed as inhibition of tumor weight at 20 mg/kg, ip after 7 days relative to control
|
Mus musculus
|
63.8
%
|
|
Growth inhibition of human HaCaT cells after 72 hrs by MTT assay
|
Homo sapiens
|
400.0
nM
|
|
Cytotoxicity against human KB cells by MTT assay
|
Homo sapiens
|
4.46
nM
|
|
Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
|
Homo sapiens
|
690.0
nM
|
|
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
|
Mus musculus
|
609.0
nM
|
|
Antiproliferative activity against mouse Colon 26-L5 cells assessed as cell viability after 72 hrs by MTT assay
|
Mus musculus
|
500.0
nM
|
|
Antiproliferative activity against mouse B16-BL6 cells assessed as cell viability after 72 hrs by MTT assay
|
Mus musculus
|
600.0
nM
|
|
Cytotoxicity against human SK-MEL cells after 2 to 7 days by neutral red assay
|
Homo sapiens
|
6.3
ug.mL-1
|
|
Cytotoxicity against human KB cells after 2 to 7 days by neutral red assay
|
Homo sapiens
|
10.0
ug.mL-1
|
|
Cytotoxicity against human SKOV3 cells after 2 to 7 days by neutral red assay
|
Homo sapiens
|
10.0
ug.mL-1
|
|
Antiproliferative activity against human HT1080 cells by MTT assay
|
Homo sapiens
|
0.29
ug.mL-1
|
|
Antiproliferative activity against mouse Colon 26-L5 cells by MTT assay
|
Mus musculus
|
0.07
ug.mL-1
|
|
Antitumor activity in mouse B16 cell xenografted mouse at 20 mg/kg/day, iv after 4 days
|
Mus musculus
|
73.5
%
|
|
Antitumor activity against mouse P388 cells
|
Mus musculus
|
0.02
ug.mL-1
|
|
Antitumor activity against human A549 cells
|
Homo sapiens
|
0.1
ug.mL-1
|
|
Antitumor activity against human HT-29 cells
|
Homo sapiens
|
0.1
ug.mL-1
|
|
Antitumor activity against human SK MEL28 cells
|
Homo sapiens
|
0.1
ug.mL-1
|
|
Cytotoxicity against human HepG2 cells by MTT assay
|
Homo sapiens
|
1.3
ug.mL-1
|
|
Cytotoxicity against human KB cells
|
Homo sapiens
|
0.93
ug.mL-1
|
|
Cytotoxicity against human HeLa S3 cells
|
Homo sapiens
|
0.44
ug.mL-1
|
|
Growth inhibition of embryonic cells of stage 8 Xenopus laevis blastulae at 10 ug/mL
|
Xenopus laevis
|
47.0
%
|
|
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy
|
Homo sapiens
|
0.9
%
|
|
Cytotoxicity against human MCF7 cells by MTT assay
|
Homo sapiens
|
0.0012
ug.mL-1
|
|
Cytotoxicity against human Hep3B cells by MTT assay
|
Homo sapiens
|
0.072
ug.mL-1
|
|
Cytotoxicity against mouse colon 26-L5 cells after 72 hrs by MTT assay
|
Mus musculus
|
460.0
nM
|
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
Homo sapiens
|
770.0
nM
|
|
Antiproliferative activity against mouse L1210 cells after 2 days by MTT assay
|
Mus musculus
|
690.0
nM
|
|
Cytotoxicity against human Bel7404 after 24 hrs by MTT assay
|
Homo sapiens
|
0.2
ug.mL-1
|
|
Cytotoxicity against human A549 after 24 hrs by MTT assay
|
Homo sapiens
|
0.2
ug.mL-1
|
|
Cytotoxicity against human BGC823 after 24 hrs by MTT assay
|
Homo sapiens
|
0.2
ug.mL-1
|
|
Cytotoxicity against human HCT8 after 24 hrs by MTT assay
|
Homo sapiens
|
0.2
ug.mL-1
|
|
Cytotoxicity against human A2780 after 24 hrs by MTT assay
|
Homo sapiens
|
0.2
ug.mL-1
|
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
Homo sapiens
|
300.0
nM
|
|
Antiproliferative activity against human T47D cells after 72 hrs by MTT assay
|
Homo sapiens
|
600.0
nM
|
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
Homo sapiens
|
16.0
nM
|
|
Antiproliferative activity against human A431 cells after 48 hrs by MTT assay
|
Homo sapiens
|
18.0
nM
|
|
Cytotoxicity against human A549 cells by SRB assay
|
Homo sapiens
|
2.0
ug.mL-1
|
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
Homo sapiens
|
0.67
ug.mL-1
|
|
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
|
Homo sapiens
|
1.01
ug.mL-1
|
|
Cytotoxicity against human U251 cells at 50 uM after 48 hrs by SRB assay
|
Homo sapiens
|
64.2
%
|
|
Cytotoxicity against human PC3 cells at 50 uM after 48 hrs by SRB assay
|
Homo sapiens
|
45.4
%
|
|
Cytotoxicity against human K562 cells at 50 uM after 48 hrs by SRB assay
|
Homo sapiens
|
73.7
%
|
|
Cytotoxicity against human HCT15 cells at 50 uM after 48 hrs by SRB assay
|
Homo sapiens
|
71.3
%
|
|
Cytotoxicity against human MCF7 cells at 50 uM after 48 hrs by SRB assay
|
Homo sapiens
|
65.1
%
|
|
Cytotoxicity against human SK-LU-1 cells at 50 uM after 48 hrs by SRB assay
|
Homo sapiens
|
70.5
%
|
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
Homo sapiens
|
440.0
nM
|
|
Cytotoxicity against mouse Colon 26-L5 cells after 72 hrs by MTT assay
|
Mus musculus
|
410.0
nM
|
|
Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay
|
Homo sapiens
|
30.0
nM
|
|
Antitumor activity against mouse S180 cells transplanted in Kunming mouse assessed as inhibition of tumor growth at 50 mg/kg/day, iv for 2 days
|
Mus musculus
|
80.7
%
|
|
Cytotoxicity against human SGC7901 after 48 hrs by MTT assay
|
Homo sapiens
|
7.38
ug.mL-1
|
|
Antiviral activity against Influenza A virus H5N1 Vietnam/1203/2004H infected in MDCK cells
|
Influenza A virus (A/Viet Nam/1203/2004(H5N1))
|
26.0
ug.mL-1
|
|
Antiviral activity against Influenza B virus Florida/4/2006 infected in MDCK cells
|
Influenza B virus (B/Florida/4/2006)
|
23.0
ug.mL-1
|
|
Cytotoxicity against MDCK cells
|
Canis lupus familiaris
|
100.0
ug.mL-1
|
|
Antitumor activity against mouse EAC cells xenografted in BALB/C mouse assessed as inhibition of tumor growth at 10 mg/kg, ip administered every 3 days measured on day 7 relative to control
|
Mus musculus
|
41.7
%
|
|
Antitumor activity against mouse EAC cells xenografted in BALB/C mouse assessed as inhibition of tumor growth at 10 mg/kg, ip administered every 3 days measured on day 15 relative to control
|
Mus musculus
|
57.6
%
|
|
Antitumor activity against mouse EAC cells xenografted in BALB/C mouse assessed as reduction of tumor weight at 10 mg/kg, ip administered every 3 days measured on day 15 relative to control
|
Mus musculus
|
46.1
%
|
|
Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
|
Homo sapiens
|
7.38
ug.mL-1
|
|
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
|
Homo sapiens
|
2.48
ug.mL-1
|
|
Cytotoxicity against human A431 cells after 48 hrs by MTT assay
|
Homo sapiens
|
2.17
ug.mL-1
|
|
Growth inhibition of human MDA-MB-231 cells at 3 uM after 96 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
3.3
%
|
|
Growth inhibition of human MDA-MB-231 cells at 5 uM after 96 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
41.6
%
|
|
Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
|
Homo sapiens
|
7.36
ug.mL-1
|
|
Anticancer activity against human Hep2 cells assessed as cell viability after 48 hrs by SRB assay
|
Homo sapiens
|
300.0
nM
|
|
PUBCHEM_BIOASSAY: A screen for inhibitors of the PhoP region in Salmonella Typhi using a modified counterscreen. (Class of assay: confirmatory)
|
None
|
378.0
nM
|
|
Cytotoxicity against human U2OS cells after 36 hrs by MTT assay
|
Homo sapiens
|
7.2
ug.mL-1
|
|
Cytotoxicity against human MCF7 cells after 36 hrs by MTT assay
|
Homo sapiens
|
34.0
ug.mL-1
|
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
Homo sapiens
|
14.1
ug.mL-1
|
|
Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
|
Homo sapiens
|
25.0
ug.mL-1
|
|
Cytotoxicity against human HepG2 cells assessed as loss of cell monolayers after 96 hrs
|
Homo sapiens
|
8.6
ug.mL-1
|
|
Cytotoxicity against human WI38 cells assessed as loss of cell monolayers after 96 hrs
|
Homo sapiens
|
3.2
ug.mL-1
|
|
Cytotoxicity against african green monkey Vero cells assessed as loss of cell monolayers after 96 hrs
|
Chlorocebus sabaeus
|
6.5
ug.mL-1
|
|
Cytotoxicity against human MCF7 cells assessed as loss of cell monolayers after 96 hrs
|
Homo sapiens
|
2.3
ug.mL-1
|
|
Cytotoxicity against mouse L1210 cells after 2 days by coulter counter analysis
|
Mus musculus
|
560.0
nM
|
|
Cytotoxicity against human HeLa cells after 4 days by coulter counter analysis
|
Homo sapiens
|
570.0
nM
|
|
Cytostatic activity against mouse L1210 cells after 2 days by coulter counting analysis
|
Mus musculus
|
560.0
nM
|
|
Cytostatic activity against mouse FM3A cells after 2 days by coulter counting analysis
|
Mus musculus
|
180.0
nM
|
|
Cytostatic activity against human HeLa cells after 3 days by coulter counting analysis
|
Homo sapiens
|
450.0
nM
|
|
Cytostatic activity against mouse L1210 cells in presence of 500 uM uridine
|
Mus musculus
|
620.0
nM
|
|
Cytostatic activity against mouse L1210 cells in presence of 500 uM uracil
|
Mus musculus
|
470.0
nM
|
|
Cytostatic activity against human HeLa cells in presence of 20 uM 2'-deoxyuridine
|
Homo sapiens
|
180.0
nM
|
|
Inhibition of DNA synthesis in mouse L1210 cells assessed as [6-3H]2'-deoxyuridine incorporation in to DNA by liquid scintillation counting
|
Mus musculus
|
970.0
nM
|
|
Inhibition of DNA synthesis in mouse L1210 cells assessed as [6-3H]2'-deoxyuridine incorporation in to DNA preincubated for 24 hrs by liquid scintillation counting
|
Mus musculus
|
370.0
nM
|
|
Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 4 hrs by liquid scintillation counting
|
Mus musculus
|
220.0
nM
|
|
Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 24 hrs by liquid scintillation counting
|
Mus musculus
|
20.0
nM
|
|
Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 4 hrs by liquid scintillation counting
|
Mus musculus
|
600.0
nM
|
|
Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 24 hrs by liquid scintillation counting
|
Mus musculus
|
60.0
nM
|
|
Cytotoxicity against mouse EAC cells assessed as cell viability using trypan blue staining after 2 hrs by hemocytometer analysis
|
Mus musculus
|
1.5
ug.mL-1
|
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability at 100 ug/mL after 48 hrs by MTT assay
|
Homo sapiens
|
7.0
%
|
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability at 50 ug/mL after 48 hrs by MTT assay
|
Homo sapiens
|
0.0
%
|
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability at 25 ug/mL after 48 hrs by MTT assay
|
Homo sapiens
|
0.0
%
|
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
|
Homo sapiens
|
0.0027
nM
|
|
Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
|
Mus musculus
|
0.0017
nM
|
|
Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay
|
Mus musculus
|
0.0011
nM
|
|
Cytotoxicity against human KB cells after 72 hrs by MTT assay
|
Homo sapiens
|
0.0077
nM
|
|
Antitumor activity against mouse S180 cells xenografted in KM mouse assessed as tumor weight inhibition rate at 25 mg/kg, ip administered qd for 9 days measured on 10th day
|
Mus musculus
|
46.5
%
|
|
Inhibition of RNA synthesis in Mucor mucedo IFO 7684 assessed as [8-14C]-adenine uptake into acid-insoluble fractions at 0.77 mM after 25 mins by liquid scintillation counting
|
Mucor mucedo
|
75.0
%
|
|
Inhibition of DNA synthesis in Mucor mucedo IFO 7684 assessed as [8-14C]-adenine uptake into acid-insoluble fractions at 0.77 mM after 25 mins by liquid scintillation counting
|
Mucor mucedo
|
61.0
%
|
|
Cytotoxicity against human MCF10A cells after 6 days by SRB colorimetric assay
|
Homo sapiens
|
730.0
nM
|
|
Cytotoxicity against rat IEC-6 cells after 6 days by SRB colorimetric assay
|
Rattus norvegicus
|
660.0
nM
|
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
Homo sapiens
|
23.31
ug.mL-1
|
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
Homo sapiens
|
31.02
ug.mL-1
|
|
Antiproliferative activity against human SW1116 cells after 48 hrs by MTT assay
|
Homo sapiens
|
28.52
ug.mL-1
|
|
Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay
|
Homo sapiens
|
17.37
ug.mL-1
|
|
Cytotoxicity against human A549 cells after 3 days by MTT assay
|
Homo sapiens
|
420.0
nM
|
|
Cytostatic activity against mouse L1210 cells
|
Mus musculus
|
490.0
nM
|
|
Cytostatic activity against human HeLa cells
|
Homo sapiens
|
540.0
nM
|
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
Homo sapiens
|
0.67
ug.mL-1
|
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
Homo sapiens
|
6.0
ug.mL-1
|
|
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
|
Homo sapiens
|
8.6
ug.mL-1
|
|
Cytotoxicity against human WI38 cells after 96 hrs by MTT assay
|
Homo sapiens
|
3.2
ug.mL-1
|
|
Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay
|
Chlorocebus sabaeus
|
6.5
ug.mL-1
|
|
Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
|
Homo sapiens
|
2.3
ug.mL-1
|
|
Cytotoxicity against human A549 cells by MTT assay
|
Homo sapiens
|
0.32
ug.mL-1
|
|
Cytotoxicity against human HeLa cells by MTT assay
|
Homo sapiens
|
0.14
ug.mL-1
|
|
Cytotoxicity against human MCF7 cells by MTT assay
|
Homo sapiens
|
0.22
ug.mL-1
|
|
Cytotoxicity against human HepG2 cells by MTT assay
|
Homo sapiens
|
0.0082
ug.mL-1
|
|
Cytotoxicity against human SMMC7721 cells by MTT assay
|
Homo sapiens
|
0.023
ug.mL-1
|
|
Cytotoxicity against human MKN45 cells by MTT assay
|
Homo sapiens
|
0.36
ug.mL-1
|
|
Cytostatic activity against mouse L1210 cells after 2 days by coulter counter analysis
|
Mus musculus
|
490.0
nM
|
|
Cytostatic activity against human HeLa cells after 3 days by coulter counter analysis
|
Homo sapiens
|
540.0
nM
|
|
Cytostatic activity against human HaCaT cells after 72 hrs by MTT assay
|
Homo sapiens
|
300.0
nM
|
|
Antitumor activity against human BxPC3 cells xenografted in SCID mouse assessed as reduction in tumor volume at 17 mg/kg, ip twice a week
|
Homo sapiens
|
3.25
%
|
|
Cytotoxicity against human NCI-H69 cells after 3 days MTT assay
|
Homo sapiens
|
280.0
ug.mL-1
|
|
Cytotoxicity against human PZ-HPV-7 cells after 3 days MTT assay
|
Homo sapiens
|
170.0
ug.mL-1
|
|
Cytotoxicity against human MCF7 cells after 3 days MTT assay
|
Homo sapiens
|
690.0
ug.mL-1
|
|
Cytotoxicity against human HeLa cells after 3 days MTT assay
|
Homo sapiens
|
40.0
ug.mL-1
|
|
Cytotoxicity against mouse EAC after 2 hrs by trypan blue staining based hemocytometer analysis
|
Mus musculus
|
97.3
ug
|
|
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
|
Homo sapiens
|
9.1
ug.mL-1
|
|
Cytotoxicity against human WI38 cells after 96 hrs by MTT assay
|
Homo sapiens
|
4.0
ug.mL-1
|
|
Cytotoxicity against African green monkey Vero cells after 96 hrs by MTT assay
|
Chlorocebus sabaeus
|
6.4
ug.mL-1
|
|
Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
|
Homo sapiens
|
2.5
ug.mL-1
|
|
Antitumor activity against human MX1 cells xenografted in Balb/cA JcL mouse at 15 mg/kg/day dosed as as continuous infusion measured on day 15
|
Homo sapiens
|
20.0
%
|
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
Homo sapiens
|
280.0
nM
|
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
|
Homo sapiens
|
60.0
nM
|
|
Antitumor activity against human MX1 cells xenografted in Balb/cA JcL-nu mouse assessed as tumor growth inhibition at 15 mg/kg/day, po for 14 days dosed as continuous infusion using osmotic pump and measured twice a week relative to untreated control
|
Homo sapiens
|
20.0
%
|
|
Cytostatic activity against human HeLa cells after 72 hrs by cell counting
|
Homo sapiens
|
540.0
nM
|
|
Cytostatic activity against thymidine-kinase deficient human HeLa cells after 72 hrs by cell counting
|
Homo sapiens
|
230.0
nM
|
|
Cytostatic activity against thymidine-kinase deficient mouse L1210 cells after 48 hrs by cell counting
|
Mus musculus
|
320.0
nM
|
|
Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay
|
Homo sapiens
|
7.2
ug.mL-1
|
|
Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
|
Homo sapiens
|
8.2
ug.mL-1
|
|
Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay
|
Homo sapiens
|
8.7
ug.mL-1
|
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
Homo sapiens
|
9.3
ug.mL-1
|
|
Cytotoxicity against Homo sapiens (human) HL60 cells by MTT assay
|
Homo sapiens
|
25.4
ug.mL-1
|
|
Cytotoxicity against Homo sapiens (human) SGC7901 cells by MTT assay
|
Homo sapiens
|
0.58
ug.mL-1
|
|
Cytotoxicity against Homo sapiens (human) HT-29 cells by MTT assay
|
Homo sapiens
|
10.26
ug.mL-1
|
|
Antiproliferative activity against Homo sapiens (human) A431 cells at 5 uM measured after 72 hr by MTT assay
|
Homo sapiens
|
30.7
%
|
|
Antiproliferative activity against Homo sapiens (human) PC3 cells at 5 uM measured after 72 hr by MTT assay
|
Homo sapiens
|
41.1
%
|
|
Antitumor activity against mouse HepS cells allografted in Kunming mouse assessed as inhibition of tumor growth at 25 mg/kg, iv bid administered 2 days once for 4 times
|
Mus musculus
|
70.31
%
|
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
Homo sapiens
|
1.28
ug.mL-1
|
|
Cytotoxicity against human U937 cells after 24 hrs by MTT assay
|
Homo sapiens
|
0.87
ug.mL-1
|
|
Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay
|
Homo sapiens
|
4.03
ug.mL-1
|
|
Cytotoxicity against human THP1 cells after 24 hrs by MTT assay
|
Homo sapiens
|
0.54
ug.mL-1
|
|
Cytotoxicity against human ACHN cells after 24 hrs by MTT assay
|
Homo sapiens
|
9.874
ug.mL-1
|
|
Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay
|
Homo sapiens
|
4.562
ug.mL-1
|
|
Cytotoxicity against human EC9706 cells after 72 hrs by MTT assay
|
Homo sapiens
|
320.0
nM
|
|
Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
|
Homo sapiens
|
970.0
nM
|
|
Antitumor activity against mouse H22 cells transfected in mouse assessed as inhibition of tumor growth at 153.8 umol/kg, ip after 14 days relative to vehicle-treated control
|
Mus musculus
|
57.55
%
|
|
Antitumor activity against mouse EAC cells by trypan blue exclusion assay
|
Mus musculus
|
380.0
nM
|
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
Homo sapiens
|
0.8
ug.mL-1
|
|
Cytotoxicity against human Hep cells after 48 hrs by SRB assay
|
Homo sapiens
|
500.0
nM
|
|
Cytotoxicity against human QSG7701 cells after 48 hrs by CCK-8 assay
|
Homo sapiens
|
600.0
nM
|
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
Homo sapiens
|
0.887
ug.mL-1
|
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
|
Homo sapiens
|
2.48
ug.mL-1
|
|
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
86.84
%
|
|
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
91.17
%
|
|
Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay
|
Homo sapiens
|
25.6
ug.mL-1
|
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
Homo sapiens
|
24.87
ug.mL-1
|
|
Cytotoxicity against human HuH7 cells after 48 hrs by MTT assay
|
Homo sapiens
|
20.03
ug.mL-1
|
|
Cytotoxicity against mouse L1210 cells assessed as reduction in cell number after 48 hrs by cell counting assay
|
Mus musculus
|
330.0
nM
|
|
Cytotoxicity against human HeLa cells assessed as reduction in cell number after 72 hrs by cell counting assay
|
Homo sapiens
|
540.0
nM
|
|
Cytotoxicity against human A549 cells assessed as growth inhibition measured at 48 hrs by SRB assay
|
Homo sapiens
|
980.0
nM
|
|
Cytotoxicity against mouse E0771 cells after 3 days by SRB assay
|
Mus musculus
|
280.0
nM
|
|
Antitumor activity against mouse B16 cells transplanted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered 7 days post tumor transplantation
|
Mus musculus
|
70.3
%
|
|
Cytotoxicity against human Hep cells after 48 hrs by SRB assay
|
Homo sapiens
|
500.0
nM
|
|
Cytotoxicity against mouse B16F10 cells assessed as inhibition of proliferation after 72 hrs by MTT assay
|
Mus musculus
|
870.0
nM
|
|
Cytotoxicity against human THP1 cells after 48 hrs by SRB assay
|
Homo sapiens
|
40.0
nM
|
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
Homo sapiens
|
10.0
nM
|
|
Cytostatic activity against mouse L1210 cells after 48 hrs by Coulter counting
|
Mus musculus
|
330.0
nM
|
|
Antitumor activity against mouse B16 cells allografted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered 7 days post inoculation measured at day 25 of tumor transplantation
|
Mus musculus
|
70.3
%
|
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
|
Homo sapiens
|
500.0
nM
|
|
Cytostatic activity against mouse L1210 cells assessed as inhibition of proliferation after 48 hrs by Coulter cell counting method
|
Mus musculus
|
330.0
nM
|
|
Cytostatic activity against human HeLa cells assessed as inhibition of proliferation after 72 hrs by Coulter cell counting method
|
Homo sapiens
|
540.0
nM
|
|
Anticancer activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
Homo sapiens
|
4.1
ug.mL-1
|
|
Anticancer activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
|
Homo sapiens
|
12.1
ug.mL-1
|
|
Anticancer activity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay
|
Homo sapiens
|
4.8
ug.mL-1
|
|
Anticancer activity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
|
Homo sapiens
|
5.7
ug.mL-1
|
|
Anticancer activity against mouse LL/2 cells assessed as growth inhibition after 48 hrs by MTT assay
|
Mus musculus
|
2.9
ug.mL-1
|
|
Antiproliferative activity against human HCT8 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
Homo sapiens
|
910.0
nM
|
|
In vivo antitumor activity against mouse B16 cells xenografted in mouse assessed as tumor growth inhibitory ratio at 30 mg/kg, ip administered after 7 days of tumor transplantation measured at 25th day after tumor inoculation
|
Mus musculus
|
70.3
%
|
|
Cytotoxicity against human T3M4 cells by crystal violet staining
|
Homo sapiens
|
330.0
nM
|
|
Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation
|
Mus musculus
|
330.0
nM
|
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation
|
Homo sapiens
|
540.0
nM
|
|
Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
Homo sapiens
|
860.0
nM
|
|
Anticancer activity against human HepG2 cells at 40 ug/ml after 72 hrs by MTT assay
|
Homo sapiens
|
68.2
%
|
|
Anticancer activity against human MCF7 cells at 40 ug/ml after 72 hrs by MTT assay
|
Homo sapiens
|
68.2
%
|
|
Antiproliferative activity against human SW620 cells incubated for 72 hrs by MTT assay
|
Homo sapiens
|
790.0
nM
|
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
Homo sapiens
|
35.99
ug.mL-1
|
|
Cytotoxicity against human BCG823 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
Homo sapiens
|
17.41
ug.mL-1
|
|
Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
Homo sapiens
|
10.41
ug.mL-1
|
|
Antitumor activity against mouse B16F10 cells xenografted in mouse assessed as inhibition of tumor growth at 20 mg/kg, iv after 25 days
|
Mus musculus
|
68.2
%
|
|
Cytotoxicity against human MCF7 cells after 72 hrs by CCK8 assay
|
Homo sapiens
|
520.0
nM
|
|
Cytotoxicity against human MDST8 cells after 72 hrs by CCK8 assay
|
Homo sapiens
|
64.0
nM
|
|
Cytotoxicity against human MDST8 cells at 1 x 10'-5 M after 72 hrs by CCK8 assay
|
Homo sapiens
|
83.0
%
|
|
Cytotoxicity against human MCF7 cells at 1 x 10'-5 M after 72 hrs by CCK8 assay
|
Homo sapiens
|
60.0
%
|
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
Homo sapiens
|
90.0
nM
|
|
Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay
|
Homo sapiens
|
790.0
nM
|
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
|
Homo sapiens
|
500.0
nM
|
|
Cytotoxicity against human THP1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
|
Homo sapiens
|
10.0
nM
|
|
Antiproliferative activity against human PANC1 cells after 72 hrs by WST-8 assay
|
Homo sapiens
|
400.0
nM
|
|
Antiproliferative activity against human MCF7 cells assessed as cellular DNA content after 96 hrs by CyQUANT NF fluorescence assay
|
Homo sapiens
|
900.0
nM
|
|
Cytotoxicity against human LNCAP cells assessed as growth inhibition after 24 hrs by sulforhodamine B assay
|
Homo sapiens
|
30.0
nM
|
|
Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by sulforhodamine B assay
|
Homo sapiens
|
30.0
nM
|
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
Homo sapiens
|
10.8
ug.mL-1
|
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
Homo sapiens
|
10.72
ug.mL-1
|
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
Homo sapiens
|
9.23
ug.mL-1
|
|
Cytotoxicity against human BCG823 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
Homo sapiens
|
10.89
ug.mL-1
|
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
Homo sapiens
|
10.5
ug.mL-1
|
|
Cytotoxicity against human HL7702 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
Homo sapiens
|
14.53
ug.mL-1
|
|
Cytotoxicity against human Bel7402 cells at 10'-5 M by MTT assay relative to control
|
Homo sapiens
|
70.57
%
|
|
Cytotoxicity against human HCT8 cells at 10'-5 M by MTT assay relative to control
|
Homo sapiens
|
70.38
%
|
|
Cytotoxicity against human A549 cells at 10'-5 M by MTT assay relative to control
|
Homo sapiens
|
68.32
%
|
|
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
Homo sapiens
|
4.8
ug.mL-1
|
|
Inhibition of wild type PI3K p110alpha/p85alpha niSH2 (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to control
|
Homo sapiens
|
25.0
%
|
|
Inhibition of full length PI3Kalpha (unknown origin) assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to control
|
Homo sapiens
|
25.0
%
|
|
Anti-proliferative activity against mouse L1210 cells measured after 48 hrs by coulter counter method
|
Mus musculus
|
330.0
nM
|
|
Anti-proliferative activity against human HeLa cells measured after 4 days by coulter counter method
|
Homo sapiens
|
540.0
nM
|
|
Antiproliferative activity against human CFPAC-1 cells after 72 hrs by MTT assay
|
Homo sapiens
|
140.0
nM
|
|
Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay
|
Homo sapiens
|
80.0
nM
|
|
Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay
|
Homo sapiens
|
940.0
nM
|
|
Antiproliferative activity against human CFPAC-1 cells after 72 hrs by MTT assay
|
Homo sapiens
|
140.0
nM
|
|
Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay
|
Homo sapiens
|
80.0
nM
|
|
Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay
|
Homo sapiens
|
940.0
nM
|
|
Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay
|
Homo sapiens
|
80.0
nM
|
|
Antiproliferative activity against human CFPAC-1 cells after 72 hrs by MTT assay
|
Homo sapiens
|
140.0
nM
|
|
Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
|
Homo sapiens
|
940.0
nM
|
|
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
Homo sapiens
|
66.0
ug.mL-1
|
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
Homo sapiens
|
178.0
ug.mL-1
|
|
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
Homo sapiens
|
201.0
ug.mL-1
|
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
Homo sapiens
|
237.0
ug.mL-1
|
|
Anticlonogenic activity against human A549 cells assessed as inhibition of clonogenic growth at 3 uM incubated for 2 days followed by replacement of growth media and measured after 8 days by crystal violet staining-based assay relative to control
|
Homo sapiens
|
38.0
%
|
|
Anticlonogenic activity against human A549 cells assessed as inhibition of clonogenic growth at 9 uM incubated for 2 days followed by replacement of growth media and measured after 8 days by crystal violet staining-based assay relative to control
|
Homo sapiens
|
70.0
%
|
|
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
|
Homo sapiens
|
19.25
ug.mL-1
|
|
Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
|
Homo sapiens
|
16.03
ug.mL-1
|
|
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
|
Homo sapiens
|
1.8
ug.mL-1
|
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
Homo sapiens
|
2.19
ug.mL-1
|
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
Homo sapiens
|
3.82
ug.mL-1
|
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
Homo sapiens
|
2.24
ug.mL-1
|
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
Homo sapiens
|
430.0
nM
|
|
Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
|
Homo sapiens
|
530.0
nM
|
|
Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 96 hrs
|
Homo sapiens
|
8.6
ug.mL-1
|
|
Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 96 hrs
|
Homo sapiens
|
3.2
ug.mL-1
|
|
Cytotoxicity against human SN12C cells assessed as decrease in cell viability after 96 hrs
|
Homo sapiens
|
6.5
ug.mL-1
|
|
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 96 hrs
|
Homo sapiens
|
2.3
ug.mL-1
|
|
Cytotoxicity against human NCI-H358 cells assessed as decrease in cell viability after 96 hrs
|
Homo sapiens
|
6.9
ug.mL-1
|
|
Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell viability after 96 hrs
|
Homo sapiens
|
3.5
ug.mL-1
|
|
Antiproliferative activity against human LS174T cells assessed as inhibition of cell proliferation at 10 uM after 4 days by Vi-Cell cell viability analyzer based method relative to control
|
Homo sapiens
|
82.3
%
|
|
Antiproliferative activity against human LS174T cells assessed as inhibition of cell proliferation at 1 uM after 4 days by Vi-Cell cell viability analyzer based method relative to control
|
Homo sapiens
|
6.5
%
|
|
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation at 1 uM after 4 days by Vi-Cell cell viability analyzer based method relative to control
|
Homo sapiens
|
11.6
%
|
|
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation at 10 uM after 4 days by Vi-Cell cell viability analyzer based method relative to control
|
Homo sapiens
|
82.9
%
|
|
Antiproliferative activity against human Caco2 cells assessed as inhibition of cell proliferation at 1 uM after 4 days by Vi-Cell cell viability analyzer based method relative to control
|
Homo sapiens
|
37.7
%
|
|
Antiproliferative activity against human Caco2 cells assessed as inhibition of cell proliferation at 10 uM after 4 days by Vi-Cell cell viability analyzer based method relative to control
|
Homo sapiens
|
60.2
%
|
|
Cytotoxicity against human HEL299 cells assessed as inhibition of cell proliferation at 10 uM after 4 days by Vi-Cell cell viability analyzer based method relative to control
|
Homo sapiens
|
64.6
%
|
|
Cytotoxicity against human HEL299 cells assessed as inhibition of cell proliferation at 1 uM after 4 days by Vi-Cell cell viability analyzer based method relative to control
|
Homo sapiens
|
12.1
%
|
|
Cytotoxicity against human BEAS2B cells assessed as inhibition of cell proliferation at 10 uM after 4 days by Vi-Cell cell viability analyzer based method relative to control
|
Homo sapiens
|
57.5
%
|
|
Cytotoxicity against human BEAS2B cells assessed as inhibition of cell proliferation at 1 uM after 4 days by Vi-Cell cell viability analyzer based method relative to control
|
Homo sapiens
|
4.5
%
|
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth at 100 uM after 72 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiproliferative activity against human HL60 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by MTT assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiproliferative activity against human K562 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by MTT assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiproliferative activity against human LS180 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiproliferative activity against human PANC1 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by sulforhodamine B assay relative to control
|
Homo sapiens
|
41.0
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
-3.59
%
|
|
Antiproliferative activity against human CFPAC-1 cells incubated for 72 hrs by MTT assay
|
Homo sapiens
|
140.0
nM
|
|
Antiproliferative activity against human SW620 cells incubated for 72 hrs by MTT assay
|
Homo sapiens
|
80.0
nM
|
|
Antiproliferative activity against human MCF7 cells by MTT assay
|
Homo sapiens
|
30.0
ug.mL-1
|
|
Reduction in CDK1 mRNA expression in human HCT116 cells at 100 nM after 6 hrs hrs by SYBR green dye-based qRT-PCR analysis relative to control
|
Homo sapiens
|
50.0
%
|
|
Cytotoxicity against human MCF7 cells
|
Homo sapiens
|
9.74
ug.mL-1
|
|
Cytotoxicity against human HCT116 cells
|
Homo sapiens
|
17.3
ug.mL-1
|
|
Cytotoxicity against human PC3 cells
|
Homo sapiens
|
21.4
ug.mL-1
|
|
Antiproliferative activity against human DLD1 cells assessed as cell growth inhibition at 450 nM by MTT assay relative to control
|
Homo sapiens
|
21.0
%
|
|
Antiproliferative activity against human NCI-N87 cells assessed as cell growth inhibition at 450 nM by MTT assay relative to control
|
Homo sapiens
|
8.0
%
|
|
Antiproliferative activity against human KYSE-30 cells assessed as cell growth inhibition at 450 nM by MTT assay relative to control
|
Homo sapiens
|
17.0
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
7.68
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
17.78
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.04
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.05
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.04
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.05
%
|
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay
|
Homo sapiens
|
540.0
nM
|
|
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by SRB assay
|
Homo sapiens
|
540.0
nM
|
|
Cytotoxicity against human U251 cells assessed as reduction in cell viability by SRB assay
|
Homo sapiens
|
540.0
nM
|
|
Anticancer activity against human MC38 cells xenografted in C57BL/6 mouse assessed as inhibition rate at 40 mg/kg, po administered once daily for 12 days relative to control
|
Mus musculus
|
34.27
%
|
|
Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability at 10 uM incubated for 72 hrs by MTT assay relative to control
|
Homo sapiens
|
65.3
%
|
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability at 10 uM incubated for 72 hrs by MTT assay relative to control
|
Homo sapiens
|
41.9
%
|
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 10 uM incubated for 72 hrs by MTT assay relative to control
|
Homo sapiens
|
44.0
%
|
|
Antiproliferative activity against human SUIT-2 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
Homo sapiens
|
910.0
nM
|
|
Antiproliferative activity against human Capan-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
Homo sapiens
|
470.0
nM
|
|
Antiproliferative activity against human PDAC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
Homo sapiens
|
560.0
nM
|
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth at 100 microM measured after 72 hrs by SRB assay
|
Homo sapiens
|
89.29
%
|
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth at 100 microM measured after 72 hrs by SRB assay
|
Homo sapiens
|
80.67
%
|
|
Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth at 100 microM measured after 72 hrs by SRB assay
|
Homo sapiens
|
90.72
%
|
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
Homo sapiens
|
690.0
nM
|
|
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
Homo sapiens
|
520.0
nM
|
|
Antiproliferative activity against human MCF-7 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
Homo sapiens
|
590.0
nM
|
|
Antiproliferative activity against human CAL-27 cells assessed as cell viability measured after 72 hrs by MTT assay
|
Homo sapiens
|
0.5
ug.mL-1
|
|
Antiproliferative activity against human SCC-9 cells assessed as cell viability measured after 72 hrs by MTT assay
|
Homo sapiens
|
12.7
ug.mL-1
|
|